Mexidol, 5%, 2 ml, 10 pcs.

Active substance:

ethylmethylhydroxypyridine succinate 50 mg;

Excipients:

 sodium metabisulfite - 0.4 mg,

water d / i - up to 1 ml.

Pharmacodynamics

Mexidol® has antihypoxic, membrane-protective, nootropic, anticonvulsant, anxiolytic effects, increases the body's resistance to stress. The drug increases the body's resistance to the effects of the main damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebrovascular accident, intoxication with alcohol and antipsychotic drugs (neuroleptics)).

Mexidol® improves cerebral metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the level of total cholesterol and LDL. Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

The mechanism of action of Mexidol® is due to its antihypoxant, antioxidant and membrane-protective action. It inhibits the processes of lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps to preserve the structural and functional organization of biomembranes and transport of neuromembranes. Mexidol® increases the dopamine content in the brain.

Mexidol® normalizes metabolic processes in the ischemic myocardium, reduces the zone of necrosis, restores and improves electrical activity and myocardial contractility, and also increases coronary blood flow in the ischemic zone, reduces the consequences of reperfusion syndrome in acute coronary insufficiency. Increases the antianginal activity of nitro drugs.

Mexidol® promotes the preservation of retinal ganglion cells and optic nerve fibers in progressive neuropathy, the causes of which are chronic ischemia and hypoxia. Improves the functional activity of the retina and optic nerve, increasing visual acuity.

Pharmacokinetics

Suction

With the introduction of Mexidol® in doses of 400-500 mg, Cmax in plasma is 3.5-4.0 μg / ml and is achieved within 0.45-0.5 hours.

Distribution

After i / m administration, the drug is determined in blood plasma for 4 hours. The average retention time of the drug in the body is 0.7-1.3 hours.

Withdrawal

It is excreted from the body in the urine mainly in glucuronoconjugated form and in small quantities - unchanged.

• acute disorders of cerebral circulation;
• traumatic brain injury, the consequences of traumatic brain injury;
• encephalopathy;
• vegetative dystonia syndrome;
• mild cognitive disorders of atherosclerotic genesis;
• anxiety disorders in neurotic and neurosis-like states;
• acute myocardial infarction (from the first day) as part of complex therapy;
• primary open-angle glaucoma of various stages, as part of complex therapy;
• relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;
• acute intoxication with antipsychotic drugs;
• acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

• increased individual sensitivity to the drug;
• acute violations of liver and kidney function.

There have not been strictly controlled clinical studies of the safety of using Mexidol® in children, during pregnancy and lactation.

From the digestive system: rarely - nausea, dry mouth.

Others: rarely - allergic reactions.

When used together, Mexidol® enhances the effect of benzodiazepine derivatives anxiolytics, antiparkinsonian (levodopa) and anticonvulsant (carbamazepine) drugs.

Mexidol® reduces the toxic effect of ethyl alcohol.

In / m or in / in (jet or drip). When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution.

Jet Mexidol® is injected slowly over 5 - 7 minutes, drip - at a speed of 40 - 60 drops per minute. The maximum daily dose should not exceed 1200 mg.

In acute disorders of cerebral circulation Mexidol® is used in the first 10-14 days - intravenous drip of 200-500 mg 2-4 times a day, then 200-250 mg intramuscularly 2 to 3 times a day for 2 weeks ...

For traumatic brain injury and the consequences of traumatic brain injury, Mexidol® is used for 10 - 15 days intravenous drip of 200 - 500 mg 2 - 4 times a day.

In case of discirculatory encephalopathy in the phase of decompensation, Mexidol® should be administered intravenously in a stream or drip at a dose of 200 - 500 mg 1 - 2 times a day for 14 days. Then i / m at 100 - 250 mg / day for the next 2 weeks.

For the course prevention of discirculatory encephalopathy, the drug is administered intramuscularly at a dose of 200 - 250 mg 2 times a day for 10 - 14 days.

For mild cognitive impairments in elderly patients and with anxiety disorders, the drug is used in / m in a daily dose of 100 - 300 mg / day. for 14 - 30 days.

In acute myocardial infarction, as part of complex therapy, Mexidol® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy of myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, funds according to indications.

In the first 5 days, in order to achieve the maximum effect, it is desirable to administer the drug intravenously, in the next 9 days Mexidol® can be administered intramuscularly.

Intravenous administration of the drug is carried out by drop infusion, slowly (in order to avoid side effects) in 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100 - 150 ml for 30 - 90 minutes. If necessary, a slow jet injection of the drug is possible, lasting at least 5 minutes.  

The introduction of the drug (intravenous or intramuscular) is carried out 3 times a day, every 8 hours. The daily therapeutic dose is 6 - 9 mg / kg of body weight per day, a single dose is 2 - 3 mg / kg of body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.

In case of open-angle glaucoma of various stages, as part of the complex therapy, Mexidol® is administered intramuscularly at 100 - 300 mg / day, 1 - 3 times a day for 14 days.

With alcohol withdrawal syndrome, Mexidol® is administered in a dose of 200 - 500 mg intravenously or intramuscularly 2 - 3 times a day for 5 - 7 days.

In case of acute intoxication with antipsychotic drugs, the drug is administered intravenously at a dose of 200-500 mg / day for 7-14 days.

In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis), the drug is prescribed on the first day, both in the preoperative and postoperative periods. The doses administered depend on the form and severity of the disease, the prevalence of the process, and the options for the clinical course. Cancellation of the drug should be made gradually only after a stable positive clinical and laboratory effect.

In acute edematous (interstitial) pancreatitis, Mexidol® is prescribed 200-500 mg 3 times a day, intravenously drip (in 0.9% sodium chloride solution) and intramuscularly. Mild severity of necrotizing pancreatitis - 100-200 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly. Average severity - 200 mg 3 times a day, intravenous drip (in 0.9% sodium chloride solution). Severe course - at a pulse dosage of 800 mg on the first day, with a two-fold administration regimen; then 200 - 500 mg 2 times a day with a gradual decrease in the daily dose.

Extremely severe course - at an initial dosage of 800 mg / day until persistent relief of manifestations of pancreatogenic shock, after stabilization of the state, 300-500 mg 2 times a day intravenously drip (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.

Symptoms: drowsiness may develop.

Mexidol can be combined with all drugs used to treat somatic diseases.

Use in pediatrics

There have been no strictly controlled clinical studies of the safety of Mexidol® in children.

Influence on the ability to drive vehicles and use mechanisms

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

In some cases, especially in susceptible patients with bronchial asthma with hypersensitivity to sulfites, severe hypersensitivity reactions may develop.

Injection